INI1-negative Tumors clinical trials at UCSF
1 research study open to eligible people
INI1 negative tumors are cancers missing a protein that normally helps stop tumor growth. At UCSF, a trial is examining the combination of nivolumab and ipilimumab in treating these cancers in children and young adults. Researchers are investigating if these drugs can enhance the body’s immune response.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Our lead scientists for INI1-negative Tumors research studies include Alyssa Reddy.
Last updated: